首页> 美国卫生研究院文献>BMC Pharmacology Toxicology >The impact of generic substitution on the activities of pharmaceutical companies - a survey from the companies perspective one year and five years after the introduction of generic substitution in finland
【2h】

The impact of generic substitution on the activities of pharmaceutical companies - a survey from the companies perspective one year and five years after the introduction of generic substitution in finland

机译:仿制药替代对制药公司活动的影响-在芬兰引入仿制药替代一年和五年后从公司角度进行的一项调查

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundMandatory generic substitution (GS) was introduced in Finland on 1 April 2003. The aim of this study was to explore and compare the impacts of GS on the activities of pharmaceutical companies representing mainly original or generic pharmaceutical products in Finland. The self-reported impact of GS from pharmaceutical companies' perspective was explored with a focus on the number of employees, the range of sales packages on the market, the marketing activities, the research and development of new pharmaceutical products and storage of pharmaceuticals.
机译:背景技术强制性通用替代品(GS)于2003年4月1日在芬兰引入。本研究的目的是探讨和比较GS对芬兰主要代表原始或仿制药产品的制药公司的活动的影响。从制药公司的角度探讨了GS的自我报告影响,重点是员工人数,市场上销售套餐的范围,营销活动,新药品的研发和药品存储。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号